# Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL

> **NCT03259529** · PHASE1,PHASE2 · COMPLETED · sponsor: **St. Petersburg State Pavlov Medical University** · enrollment: 30 (actual)

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** Bendamustine hydrochloride
- **DRUG:** Gemcitabine 500 mg
- **DRUG:** Gemcitabine 700 mg
- **DRUG:** Gemcitabine 1000 mg
- **DRUG:** Nivolumab
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT03259529
- **Lead sponsor:** St. Petersburg State Pavlov Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-27
- **Primary completion:** 2020-01-27
- **Final completion:** 2020-01-27
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03259529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03259529, "Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03259529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*